203 related articles for article (PubMed ID: 34897643)
1. [Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
López-Ariztegui N; Mata-Alvarez Santullano M; Tegel I; Almeida F; Sarasa P; Rojo R; Rico-Villademoros F; Abril-Jaramillo J; Bermejo P; Borrue C; Caballol N; Campins-Romeu M; Clavero P; García-Caldentey J; Gómez-Mayordomo V; Labandeira C; Martí-Andrés G; Martínez-Castrillo JC; Martinez-Poles J; Muñoz T; Salom JM; Valderrama-Martín C; Vinagre-Aragón A
Rev Neurol; 2021 Dec; 73(s02):S01-S14. PubMed ID: 34897643
[TBL] [Abstract][Full Text] [Related]
2. Opicapone: A Review in Parkinson's Disease.
Scott LJ
CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
[TBL] [Abstract][Full Text] [Related]
3. Opicapone: A Review in Parkinson's Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
[TBL] [Abstract][Full Text] [Related]
4. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
5. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
[TBL] [Abstract][Full Text] [Related]
6. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Ferreira JJ
Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
[TBL] [Abstract][Full Text] [Related]
9. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
[TBL] [Abstract][Full Text] [Related]
10. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
[TBL] [Abstract][Full Text] [Related]
11. Safety Profile of Opicapone in the Management of Parkinson's Disease.
Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
[TBL] [Abstract][Full Text] [Related]
12. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
13. Opicapone for Parkinson's disease: clinical evidence and future perspectives.
Leung C; Rascol O; Fabbri M
Neurodegener Dis Manag; 2021 Jun; 11(3):193-206. PubMed ID: 33745288
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
[TBL] [Abstract][Full Text] [Related]
15. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
[No Abstract] [Full Text] [Related]
16. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K
J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498
[TBL] [Abstract][Full Text] [Related]
17. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
[TBL] [Abstract][Full Text] [Related]
18. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Katsaiti I; Nixon J
J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
Wu W; Lu X; Zhang L; Hong D
Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
[TBL] [Abstract][Full Text] [Related]
20. The launch of opicapone for Parkinson's disease: negatives versus positives.
Castro Caldas A; Teodoro T; Ferreira JJ
Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
